  0 Table of Contents |
  1 Home |
| 2 Background |
 3 Artifacts Summary |
 3.1 ICR Campaign — target geography |
| 3.2 ICR Location — H3 cell |
| 3.3 ICR Location — quadkey cell |
| 3.4 ICR Target Population — geography |
| 3.5 ICR Administrative Coverage Measure |
| 3.6 ICR Campaign Cost Measure |
| 3.7 ICR Campaign Readiness Measure |
| 3.8 ICR Geographic Coverage Measure |
| 3.9 ICR MDA Treatment Coverage Measure |
| 3.10 ICR Survey Coverage Measure |
| 3.11 ICR Zero-dose Coverage Measure |
| 3.12 ICR Campaign Readiness Checklist |
| 3.13 ICR MDA Supervision Checklist |
| 3.14 ICR Administrative Coverage |
| 3.15 ICR Adverse Event |
| 3.16 ICR Campaign |
| 3.17 ICR Campaign Activity |
| 3.18 ICR Campaign Cost |
| 3.19 ICR Campaign Form Response |
| 3.20 ICR Campaign Protocol |
| 3.21 ICR Campaign Task |
| 3.22 ICR Care Team |
| 3.23 ICR Consent (Person-Data Governance) |
| 3.24 ICR Cost Report |
| 3.25 ICR Delivery Unit (Household / Community / School Cohort) |
| 3.26 ICR Facility Organization |
| 3.27 ICR Immunization Event |
| 3.28 ICR Location |
| 3.29 ICR Location Status |
| 3.30 ICR Medication Administration |
| 3.31 ICR Patient (Beneficiary / Registered Individual) |
| 3.32 ICR Supply Distribution |
| 3.33 ICR Supply Movement |
| 3.34 ICR Survey Coverage |
| 3.35 ICR Target Population |
| 3.36 Campaign |
| 3.37 Campaign Round |
| 3.38 Confidence Interval |
| 3.39 Cost Allocation |
| 3.40 Cost Lineage |
| 3.41 Cost Perspective |
| 3.42 Cost Scope |
| 3.43 Coverage Source |
| 3.44 Coverage Unit |
| 3.45 Delivery Strategy |
| 3.46 Denominator Source |
| 3.47 Denominator Type |
| 3.48 Directly Observed Consumption |
| 3.49 Distribution Recipient |
| 3.50 Dose-pole Band |
| 3.51 Estimate Confidence |
| 3.52 Estimate Date |
| 3.53 Funding Source |
| 3.54 Group Location |
| 3.55 Is Calculated |
| 3.56 Is Planning Denominator |
| 3.57 Issued To Team |
| 3.58 Location Boundary (GeoJSON) |
| 3.59 Oversees Area |
| 3.60 Planning Denominator |
| 3.61 Prior-dose Status (Zero-dose) |
| 3.62 Real-time vs Reconciled |
| 3.63 Record Origin |
| 3.64 Reporter Team |
| 3.65 Sample Design |
| 3.66 Serious-Event Criteria |
| 3.67 Settlement / Special-population Type |
| 3.68 Social Mobilization |
| 3.69 Spatial Index Cell |
| 3.70 Stock Accountability |
| 3.71 Target Geography |
| 3.72 Task Origin |
| 3.73 Workload Target |
| 3.74 ICR Adverse Event Causality |
| 3.75 ICR Adverse Event Seriousness |
| 3.76 ICR Campaign Type |
| 3.77 ICR Communication Channel |
| 3.78 ICR Cost Allocation Basis |
| 3.79 ICR Cost Category |
| 3.80 ICR Cost Figure |
| 3.81 ICR Cost Lineage |
| 3.82 ICR Cost Perspective |
| 3.83 ICR Cost Scope |
| 3.84 ICR Coverage Source |
| 3.85 ICR Coverage Stratifier |
| 3.86 ICR Coverage Unit |
| 3.87 ICR Data Lineage |
| 3.88 ICR Delivery Strategy |
| 3.89 ICR Denominator Source |
| 3.90 ICR Denominator Type |
| 3.91 ICR Dose History / Zero-dose Status |
| 3.92 ICR Endemicity Status |
| 3.93 ICR Exclusion Reason |
| 3.94 ICR Facility Ownership |
| 3.95 ICR Facility Type |
| 3.96 ICR Funding Source |
| 3.97 ICR Group Kind |
| 3.98 ICR Independent Coverage Source |
| 3.99 ICR Location Status |
| 3.100 ICR Location Type |
| 3.101 ICR MDA Medication |
| 3.102 ICR MDA Medicine Package |
| 3.103 ICR Missed Reason |
| 3.104 ICR NTD Disease |
| 3.105 ICR Record Origin |
| 3.106 ICR Refusal Reason |
| 3.107 ICR Revisit Outcome |
| 3.108 ICR Serious-Event Criteria |
| 3.109 ICR Settlement / Special-population Type |
| 3.110 ICR Spatial Index Scheme |
| 3.111 ICR Supplied Item |
| 3.112 ICR Task Origin |
| 3.113 ICR Task Output Type |
| 3.114 ICR Team Role |
| 3.115 ICR Adverse Event Causality |
| 3.116 ICR Campaign Type |
| 3.117 ICR Commodity Class |
| 3.118 ICR Communication Channel |
| 3.119 ICR Cost Allocation Basis |
| 3.120 ICR Cost Category |
| 3.121 ICR Cost Component |
| 3.122 ICR Cost Figure |
| 3.123 ICR Cost Lineage |
| 3.124 ICR Cost Perspective |
| 3.125 ICR Cost Scope |
| 3.126 ICR Coverage Source |
| 3.127 ICR Coverage Stratifier |
| 3.128 ICR Coverage Unit |
| 3.129 ICR Data Lineage |
| 3.130 ICR Delivery Strategy |
| 3.131 ICR Denominator Source |
| 3.132 ICR Denominator Type |
| 3.133 ICR Dose History / Zero-dose Status |
| 3.134 ICR Endemicity Status |
| 3.135 ICR Exclusion Reason |
| 3.136 ICR Facility Ownership |
| 3.137 ICR Facility Type |
| 3.138 ICR Funding Source |
| 3.139 ICR Group Characteristic |
| 3.140 ICR Group Kind |
| 3.141 ICR Location Status |
| 3.142 ICR Location Type |
| 3.143 ICR MDA Medicine Package |
| 3.144 ICR Missed Reason |
| 3.145 ICR NTD Disease |
| 3.146 ICR Project Tag |
| 3.147 ICR Record Origin |
| 3.148 ICR Refusal Reason |
| 3.149 ICR Revisit Outcome |
| 3.150 ICR Serious-Event Criteria |
| 3.151 ICR Settlement / Special-population Type |
| 3.152 ICR Spatial Index Scheme |
| 3.153 ICR Task Origin |
| 3.154 ICR Task Output Type |
| 3.155 ICR Team Role |
| 3.156 ICR ↔ WHO IMMZ AEFI Causality |
| 3.157 Administer albendazole — MDA activity definition |
| 3.158 Administer MCV — campaign activity definition |
| 3.159 Administrative coverage — Kambia MR SIA, June 2026 round |
| 3.160 Adverse event — abdominal pain following albendazole |
| 3.161 AEFI — anaphylaxis following MCV dose (serious) |
| 3.162 AEFI — fever following MCV dose |
| 3.163 Albendazole administration — MDA register entry |
| 3.164 Albendazole issue — CDD team 7, day 1 (field-team daily stock) |
| 3.165 Albendazole receipt — Rokupr community (ATC-coded drug supply) |
| 3.166 Campaign readiness roll-up — Kambia, pre-campaign validation |
| 3.167 Care team — CDD team 7, Rokupr |
| 3.168 Community-directed MDA — Rokupr, albendazole round |
| 3.169 Cost line — MR vaccine, national procurement (actual, umbrella campaign) |
| 3.170 Cost line — transport & fuel, Kambia round (actual) |
| 3.171 Cost line — vaccinator per diems, Kambia round (actual) |
| 3.172 Cost line — vaccinator per diems, Kambia round (budgeted) |
| 3.173 Cost report — Kambia MR SIA, June 2026 round (actual · financial · delivery-only) |
| 3.174 Cost report — Kambia MR SIA, June 2026 round (actual · financial · full · fully-loaded) |
| 3.175 Distribute ITNs — activity definition |
| 3.176 ESPEN MDA — 1. Location Registration Form |
| 3.177 ESPEN MDA — 2. Medicine Receipt Form |
| 3.178 ESPEN MDA — 3. Medicine Treatment Form (tally) |
| 3.179 ESPEN MDA — 4. Medicine Use & Case Management Form |
| 3.180 ESPEN MDA — 5. Supervision: Health Facility |
| 3.181 ESPEN MDA — 6. Supervision: CDD Observation |
| 3.182 Example Child |
| 3.183 Example Community — Rokupr |
| 3.184 Example Consent — registry data sharing |
| 3.185 Example Country |
| 3.186 Example District |
| 3.187 Example Dwelling |
| 3.188 Example Facility Organization — Rokupr CHC |
| 3.189 Example Facility — Rokupr CHC (place) |
| 3.190 Example Fixed Post — Rokupr CHC |
| 3.191 Example Head of Household |
| 3.192 Example Household |
| 3.193 Example Household — fully enumerated |
| 3.194 Example School Cohort — Rokupr Primary School |
| 3.195 Example School — Rokupr Primary School |
| 3.196 Example Settlement |
| 3.197 Example Sibling |
| 3.198 Example Supervisory Area |
| 3.199 Example Target Population — at-risk population, Rokupr community (STH MDA) |
| 3.200 Example Target Population — children 9m–14y, Kambia District |
| 3.201 Example Target Population — children 9m–14y, Kambia District (enumeration estimate) |
| 3.202 Example Target Population — children 9m–14y, Kambia District (sum of ward microplan estimates, calculated) |
| 3.203 Example Target Population — children 9m–14y, Sierra Leone (national) |
| 3.204 Example Target Population — population protected, Rokupr IRS |
| 3.205 Example Target Population — school-aged children 5–14, Kambia District (descoped round) |
| 3.206 Example Ward — national DHIS2 code only |
| 3.207 Follow-up revisit — missed child, Rokupr block 4 |
| 3.208 Geographic coverage — Kambia MDA (villages treated / total) |
| 3.209 IRS protocol — annual indoor residual spraying |
| 3.210 IRS Rokupr — 2026 annual round |
| 3.211 IRS structure visit — Rokupr block 4, house 12 |
| 3.212 ITN distribution to household |
| 3.213 Kambia MR SIA — June 2026 round |
| 3.214 Kambia SCH MDA 2026 — descoped round (SAC only, supply-constrained) |
| 3.215 LF endemicity — Kambia District (endemic, under MDA) |
| 3.216 LQAS lot assessment — Kambia MR SIA, June 2026 round |
| 3.217 MCV dose — campaign record |
| 3.218 MDA treatment coverage — Rokupr albendazole round (sex × age stratified) |
| 3.219 Measles–Rubella SIA Protocol |
| 3.220 Mop-up household visit — Rokupr block 4, house 12 |
| 3.221 Onchocerciasis endemicity — Kambia District (non-endemic) |
| 3.222 Post-campaign survey coverage — Kambia MR SIA, June 2026 round |
| 3.223 Readiness validation — Kambia supervision zone 2 |
| 3.224 Schistosomiasis MDA protocol — national policy: everyone 2+ |
| 3.225 School session — praziquantel MDA at Rokupr Primary School |
| 3.226 Sierra Leone MR SIA 2026 — national umbrella campaign |
| 3.227 Site session — Rokupr CHC fixed post, campaign day 3 |
| 3.228 Spray structure — IRS activity definition |
| 3.229 STH MDA eligible population — school-age children 5–14 years (definitional) |
| 3.230 STH MDA protocol — albendazole, community-directed |
| 3.231 STH MDA, Rokupr community — February 2026 round |
| 3.232 Supervision report — CDD observation, Rokupr |
| 3.233 Zero-dose reach — Kambia MR SIA, June 2026 round |
| 3.234 ICR campaign calendar |
| 3.235 ICR coverage reports |
| 3.236 ICR coverage strata |
| 3.237 ICR location status |
 3.238 ICR target populations |
